TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
CRDF

Cardiff Oncology Inc

Healthcare · Biotechnology

1.30$ -2.3% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow CRDF
Line item 2005 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– -189.2% -786.2% -749.1% -1,096.6% -2,822.5% -4,545.5% -7,066.8% -8,147.0% -4,610.1% -3,492.1% -5,423.7% -4,457.6% -6,417.8% -8,761.7% -6,329.3% -5,518.7% -6,395.1%
– 7.7% 3.2% 4.0% 8.4% 50.3% 83.9% 121.0% 280.8% 247.1% 227.2% 201.9% 127.3% 125.6% 61.1% 81.6% 59.2% 152.4%
– – 122.7% 97.4% 118.3% 763.5% 739.4% 1,260.7% 1,969.6% 794.7% 575.4% 361.8% 482.2% 900.8% 1,102.6% 924.0% 696.9% 960.0%
– – – – – 1,190.5% 221.2% 1,494.3% 1,474.9% 657.1% 552.9% 350.2% 568.3% 821.7% 1,102.8% – – –
– -55.4% 18.2% 236.7% -183.2% 415.8% 156.4% -44.1% 285.6% -619.0% 25.9% 446.4% -178.8% -498.3% -98.4% 1,345.9% 464.4% 367.5%
– 1.5% 10.4% 0.6% 60.0% 250.5% 129.7% 716.0% 216.0% 19.8% 1.3% 27.8% 57.9% 57.1% 231.1% 119.3% 11.7% 7.4%
– -1.5% -49.9% -0.6% -60.0% -250.5% -107.1% -713.6% -6,517.8% 4,745.0% 6.1% -27.6% -57.9% -36,615.0% 9,883.2% 7,417.0% 2,010.0% 226.3%
– – – – – – 8,219.6% 7,744.4% 6,362.2% 4,800.0% 6,412.7% 9,908.8% 6,623.0% 6.7% 107.3% – – –
– 226.2% – – – 8,666.6% – 20,276.6% 6,362.2% 4,971.5% 8,485.2% 4,953.3% 6,623.0% 9,874.7% 19.4% – – –
– – – – – 199.0% 5,172.9% 347.0% -92.1% -3,413.7% -363.9% – – 0.0% – – – –
– 253.8% 653.0% 998.7% 3,405.4% 8,865.6% 5,172.9% 20,623.6% 604.0% -1,263.0% 4,339.6% 4,937.2% 37,517.0% 9,874.7% 19.4% 0.0% 7,874.1% 435.2%
– 63.1% -183.1% 249.0% 2,248.8% 5,792.6% 520.3% 12,843.2% -14,062.5% -1,126.5% 853.7% -514.2% 33,001.5% -33,158.2% 1,140.9% 1,087.7% 4,365.3% -5,733.6%
– -190.8% -796.7% -749.7% -1,156.6% -3,073.0% -4,675.2% -7,782.8% -8,363.0% -4,629.9% -3,493.4% -5,451.5% -4,515.5% -6,474.9% -8,992.7% -6,448.6% -5,530.5% -6,402.5%

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?